Bayleyegn Derso Teketay, Mengistu Bemrew Admassu, Demessie Yitayew, Fenta Melkie Dagnaw, Getnet Kalkidan
School of Veterinary Medicine, Mersa Agriculture College, Woldia University, Wollo, Ethiopia.
2 Department of Biomedical Sciences, College of Veterinary Medicine and Animal Sciences, Univeristy of Gondar, Gondar, Ethiopia.
Front Mol Med. 2025 Jun 19;5:1569717. doi: 10.3389/fmmed.2025.1569717. eCollection 2025.
The idea of using stem cell therapy to treat neurodegenerative diseases has undergone significant change over the years and has made significant progress recently. Neurotrophins, growth factors, and transcription factors regulate neural stem cell proliferation and differentiation. Disruption of these regulatory mechanisms, including negative feedback, can contribute to neurodegenerative diseases. Contemporary research highlights a growing global concern regarding diverse neurodegenerative disorders affecting both humans and animals. These conditions arise from neuronal cell death, axonal regeneration failure, and impairment of neuronal structure. Current pharmacological treatments primarily offer symptomatic relief without altering disease progression. Consequently, researchers are investigating innovative therapeutic strategies, with neural stem cell therapy emerging as a promising avenue. Adult neural stem cells, embryonic neural stem cells, and induced pluripotent stem cells represent potential cell sources, although challenges such as ethical considerations and technical limitations remain. The therapeutic application of neural stem cells holds significant promise for addressing neurodegenerative diseases, including Alzheimer's disease, stroke, amyotrophic lateral sclerosis, spinal cord injury, and multiple sclerosis. Neural stem cell therapy aims to replenish lost neurons and promote neural regeneration in these conditions. While clinical trials have demonstrated some success in improving cognitive and motor functions in individuals with neurodegenerative impairments, challenges such as immunological rejection, the identification of compatible cell sources, ethical concerns, treatment efficacy, and potential side effects necessitate thorough investigation before widespread clinical implementation. Despite these challenges, neural stem cell-based therapy offers substantial potential for revolutionizing the treatment of neurodegenerative diseases and central nervous system injuries. This paper, therefore, explores adult neurogenesis and the therapeutic potential of neural stem cells within the dynamic field of neurodegenerative disorders.
多年来,使用干细胞疗法治疗神经退行性疾病的理念发生了重大变化,并且最近取得了显著进展。神经营养因子、生长因子和转录因子调节神经干细胞的增殖和分化。这些调节机制的破坏,包括负反馈,可导致神经退行性疾病。当代研究凸显了全球对影响人类和动物的各种神经退行性疾病日益增长的关注。这些病症源于神经元细胞死亡、轴突再生失败以及神经元结构受损。目前的药物治疗主要提供症状缓解,而不会改变疾病进程。因此,研究人员正在研究创新的治疗策略,神经干细胞疗法成为一条有前景的途径。成体神经干细胞、胚胎神经干细胞和诱导多能干细胞是潜在的细胞来源,尽管存在伦理考量和技术限制等挑战。神经干细胞的治疗应用在治疗神经退行性疾病方面具有重大前景,包括阿尔茨海默病、中风、肌萎缩侧索硬化症、脊髓损伤和多发性硬化症。神经干细胞疗法旨在在这些情况下补充丢失的神经元并促进神经再生。虽然临床试验已在改善神经退行性损伤个体的认知和运动功能方面取得了一些成功,但免疫排斥、兼容细胞来源的鉴定、伦理问题、治疗效果和潜在副作用等挑战在广泛临床应用之前需要进行彻底研究。尽管存在这些挑战,但基于神经干细胞的疗法在彻底改变神经退行性疾病和中枢神经系统损伤的治疗方面具有巨大潜力。因此,本文探讨了成体神经发生以及神经干细胞在神经退行性疾病动态领域中的治疗潜力。